Industry-sponsored clinical research: a double-edged sword.
about
Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemiaMaterializing research promises: opportunities, priorities and conflicts in translational medicineEquipoise, design bias, and randomized controlled trials: the elusive ethics of new drug developmentThe benefits and threats of research partnerships with industryStrengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborationsPublic welfare agenda or corporate research agenda?Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative studyAlteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.Early Toronto experience with new standards for industry-sponsored clinical research: a progress report.Toward a definition of pharmaceutical innovation.Industry sponsorship and authorship of clinical trials over 20 years.Prevalence and determinants of physician participation in conducting pharmaceutical-sponsored clinical trials and lectures.Ethical issues in molecular medicine of relevance to surgeons.Industry-sponsored economic studies in critical and intensive care versus studies sponsored by nonprofit organizations.Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritisInstitutional conflicts of interest: protecting human subjects, scientific integrity, and institutional accountability.A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study designNew Devices Designed to Improve the Long-Term Results of Endovascular Treatment of Intracranial Aneurysms. A Proposition for a Randomized Clinical Trial to Assess their Safety and EfficacyScientific publications in obstetrics and gynecology journals from China, 2000-2009.Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisationsWhat is effective care for varicose veins?Delivery of Essential Medicines to Primary Care Institutions and its Association with Procurement Volume and Price: A Case Study in Hubei Province, China.Getting it right: industry sponsorship and medical research.Scientific publications in urology and nephrology journals from China: A 10-year analysis.Selective serotonin reuptake inhibitors.A postmodern moral tale: the ethics of research relationships.Balancing cost-effectiveness with quality in tissue viability.The human subjects trade: ethical and legal issues surrounding recruitment incentives.National guidelines for high-cost drugs in Brazil: achievements and constraints of an innovative national evidence-based public health policy.Factor VIIa for ICH: behind the scenes of an academic-industry collaborative trial.
P2860
Q24246566-9BD61C21-E7D8-43B9-B9F2-021A1A57009AQ24797709-B759CB17-B5F5-4210-985E-2222DD12AA1CQ24800828-F0328681-9DBF-49EF-943B-6E4DE7AE20B9Q24810516-496636C5-219E-49A0-B21A-2FD624E72729Q28652262-8838560C-85F0-458C-A89D-2B9D0B2265E7Q28728749-2F5FAB23-D380-4DC8-820C-4C9568E6CC09Q28763783-0C79C138-57FF-45F6-9FBE-E4A4C12CDC99Q33809694-81A2D443-1966-44B0-BAA3-C1434D5AF76DQ34011069-95E52D7C-E16F-469E-9080-54B3DDEF95C6Q34186669-FE8BE3DB-66B6-4493-8A9D-6C8F279EB77DQ34300884-8375B26E-FEB6-4AF0-8200-D4D4A44A6BD3Q34740740-526C5581-6825-49CC-9E62-FB7C6582FB06Q35537370-733ADC63-1C8B-4A77-BB40-13014FEB5B57Q35702246-0785C0AF-F08D-47B3-9C3C-5CE2B754CE00Q36040059-6C5EACE3-787D-41B1-A7A4-2768393D072BQ36088088-416CF65B-19C4-4FF1-A8A6-BB05FFE8E5E8Q37515050-1EDE3DF2-4A6B-405B-90B3-F19C8C5BA281Q37768555-39613255-F2F2-4078-893D-875F7F2ACDCFQ38131184-11B158D7-4E92-4320-87FC-F60C9AB8EB0AQ38602607-0B9C2CC5-74B8-4C47-BABA-C51C3E601BB5Q38750761-AC7ADC60-2A16-4B5C-97FD-6CFFC16B8FC7Q39404874-29CE6FEC-A810-42AE-B11E-FE7A92E42344Q39749441-0C4B0F79-1817-479F-A42C-236EABC2EBD2Q42153552-A74A3113-9E72-4DD9-966B-FE00AB768297Q42409877-2DB4D9B2-BE5C-47E2-B6D8-26C0492B179CQ44065550-3D9FC0B1-3EFA-4921-9968-BF025ED9788BQ44639367-5CE980A7-5016-4F80-A027-C9CC2D108004Q48571469-CEE17BF4-AD1C-4196-A6BD-5A7540C7C285Q51820485-DC45F619-E42F-4474-A890-2494AB8A6371Q53133990-E0425766-F190-436C-B30E-BA7384CC90D2
P2860
Industry-sponsored clinical research: a double-edged sword.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Industry-sponsored clinical research: a double-edged sword.
@ast
Industry-sponsored clinical research: a double-edged sword.
@en
Industry-sponsored clinical research: a double-edged sword.
@nl
type
label
Industry-sponsored clinical research: a double-edged sword.
@ast
Industry-sponsored clinical research: a double-edged sword.
@en
Industry-sponsored clinical research: a double-edged sword.
@nl
prefLabel
Industry-sponsored clinical research: a double-edged sword.
@ast
Industry-sponsored clinical research: a double-edged sword.
@en
Industry-sponsored clinical research: a double-edged sword.
@nl
P2093
P1433
P1476
Industry-sponsored clinical research: a double-edged sword.
@en
P2093
J S Montaner
M T Schechter
M V O'Shaughnessy
P304
P356
10.1016/S0140-6736(01)06891-X
P407
P577
2001-12-01T00:00:00Z